One of these demonstrated, via 18 ovarian cancer cell lines (cisplatin sensitive and resistant models), sensitization to cisplatin and a correlation of the effect observed with those bearing PI3K-activations mutations or PTEN deletions. The gene discussed is PIK3CA; the disease is ovarian cancer.